Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Administration of vincristine in a patient with Machado-Joseph disease.

Literature DB >> 22433430

Administration of vincristine in a patient with Machado-Joseph disease.

Anna Colpo¹, Frederick H Wilson, Valentina Nardi, Ephraim Hochberg.

Abstract

Chemotherapy-induced peripheral neurotoxicity is a major problem because it represents the dose-limiting side effect of a significant number of antineoplastic drugs, such as vinca alkaloids. Hereditary neuropathies usually predispose to severe vincristine neurotoxicity. Here, we report the case of a 56-year-old man with Machado-Joseph disease, also known as spinocerebellar ataxia type 3, treated with a vinca alkaloid without exacerbation of neurological symptoms.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2012 PMID： 22433430 PMCID： PMC3701890 DOI： 10.1159/000336602

Source DB: PubMed Journal: Oncology ISSN： 0030-2414 Impact factor: 2.935

16 in total

Review 1. Chemotherapy-induced peripheral neuropathy.

Authors: Stefan Quasthoff; Hans Peter Hartung
Journal: J Neurol Date: 2002-01 Impact factor: 4.849

2. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.

Authors: Laurie H Sehn; Jane Donaldson; Mukesh Chhanabhai; Catherine Fitzgerald; Karamjit Gill; Richard Klasa; Nicol MacPherson; Susan O'Reilly; John J Spinelli; Judy Sutherland; Kenneth S Wilson; Randy D Gascoyne; Joseph M Connors
Journal: J Clin Oncol Date: 2005-06-13 Impact factor: 44.544

3. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.

Authors: Laurie H Sehn; Brian Berry; Mukesh Chhanabhai; Catherine Fitzgerald; Karamjit Gill; Paul Hoskins; Richard Klasa; Kerry J Savage; Tamara Shenkier; Judy Sutherland; Randy D Gascoyne; Joseph M Connors
Journal: Blood Date: 2006-11-14 Impact factor: 22.113

4. Acute deterioration of Charcot-Marie-Tooth disease IA (CMT IA) following 2 mg of vincristine chemotherapy.

Authors: G Hildebrandt; E Holler; M Woenkhaus; G Quarch; A Reichle; B Schalke; R Andreesen
Journal: Ann Oncol Date: 2000-06 Impact factor: 32.976

5. Early recognition of hereditary motor and sensory neuropathy type 1 can avoid life-threatening vincristine neurotoxicity.

Authors: R Naumann; J Mohm; U Reuner; F Kroschinsky; B Rautenstrauss; G Ehninger
Journal: Br J Haematol Date: 2001-11 Impact factor: 6.998

6. Low dose vincristine-induced severe polyneuropathy in a Hodgkin lymphoma patient: a case report (vincristine-induced severe polyneuropathy).

Authors: Timucin Cil; Abdullah Altintas; Yusuf Tamam; Esra Battaloğlu; Abdurrahman Isikdogan
Journal: J Pediatr Hematol Oncol Date: 2009-10 Impact factor: 1.289

7. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project.

Authors: J O Armitage; D D Weisenburger
Journal: J Clin Oncol Date: 1998-08 Impact factor: 44.544

Administration of vincristine in a patient with Machado-Joseph disease.

Review 1. Chemotherapy-induced peripheral neuropathy.

2. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.

3. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.

4. Acute deterioration of Charcot-Marie-Tooth disease IA (CMT IA) following 2 mg of vincristine chemotherapy.

5. Early recognition of hereditary motor and sensory neuropathy type 1 can avoid life-threatening vincristine neurotoxicity.

6. Low dose vincristine-induced severe polyneuropathy in a Hodgkin lymphoma patient: a case report (vincristine-induced severe polyneuropathy).

7. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project.

8. Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A.

Review 9. New insights into the pathoanatomy of spinocerebellar ataxia type 3 (Machado-Joseph disease).

10. Prospective study of peripheral neuropathy in Machado-Joseph disease.

1. Micheliolide derivative DMAMCL inhibits glioma cell growth in vitro and in vivo.